DE60036382D1 - Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren - Google Patents

Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren

Info

Publication number
DE60036382D1
DE60036382D1 DE60036382A DE60036382A DE60036382D1 DE 60036382 D1 DE60036382 D1 DE 60036382D1 DE 60036382 A DE60036382 A DE 60036382A DE 60036382 A DE60036382 A DE 60036382A DE 60036382 D1 DE60036382 D1 DE 60036382D1
Authority
DE
Germany
Prior art keywords
plasma protein
administration
binding
drug
saffinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60036382A
Other languages
English (en)
Other versions
DE60036382T4 (de
DE60036382T2 (de
Inventor
Keiichi Kawai
Norito Takamura
Ryuichi Nishii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Original Assignee
Nihon Medi Physics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Medi Physics Co Ltd filed Critical Nihon Medi Physics Co Ltd
Application granted granted Critical
Publication of DE60036382D1 publication Critical patent/DE60036382D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
DE60036382A 1999-06-21 2000-06-21 Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren Expired - Lifetime DE60036382D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17351499 1999-06-21
PCT/JP2000/004039 WO2000078352A1 (fr) 1999-06-21 2000-06-21 Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede

Publications (1)

Publication Number Publication Date
DE60036382D1 true DE60036382D1 (de) 2007-10-25

Family

ID=15961945

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60036382A Expired - Lifetime DE60036382D1 (de) 1999-06-21 2000-06-21 Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren
DE60036382T Expired - Lifetime DE60036382T4 (de) 1999-06-21 2000-06-21 Verfahren zur Verabreichung von Arzneimitteln mit Bindungsaffinität zu Plasmaprotein und Präparat zur Verwendung in dem Verfahren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60036382T Expired - Lifetime DE60036382T4 (de) 1999-06-21 2000-06-21 Verfahren zur Verabreichung von Arzneimitteln mit Bindungsaffinität zu Plasmaprotein und Präparat zur Verwendung in dem Verfahren

Country Status (8)

Country Link
US (2) US7029653B1 (de)
EP (1) EP1197227B9 (de)
JP (1) JP4343473B2 (de)
AT (1) ATE372785T1 (de)
CA (1) CA2376159C (de)
DE (2) DE60036382D1 (de)
ES (1) ES2290042T3 (de)
WO (1) WO2000078352A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343473B2 (ja) * 1999-06-21 2009-10-14 日本メジフィジックス株式会社 血漿蛋白質に結合親和性を有する薬剤の投与方法並びに当該投与方法に用いられる製剤
JPWO2004024188A1 (ja) * 2002-09-12 2006-01-05 日本メジフィジックス株式会社 薬物の血漿蛋白質結合を制御するための製剤
CA2500866C (en) 2002-10-31 2013-06-25 Nihon Medi-Physics Co., Ltd. Method of measuring binding site on plasma protein of plasma protein-binding drug and method of measuring plasma protein mutation
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
CN105745030B (zh) * 2014-03-13 2022-04-15 斯泰瓦纳托集团国际 A.S. 处理液体药物制剂的方法
CN117030905B (zh) * 2023-10-09 2024-01-05 成都华西海圻医药科技有限公司 一种快速定量血浆中丁二酮浓度的lc-ms/ms分析方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520112A (en) * 1983-03-09 1985-05-28 The Johns Hopkins University Assay method for organic calcium antagonist drugs and a kit for such an assay
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US4976950A (en) 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
EP0932399B1 (de) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Wasserlösliche paclitaxel-prodrogen
DE19648629A1 (de) 1996-11-12 1998-05-14 Meisegeier Bernhard Dr Verfahren zur immunologischen Erfassung und Produktion von Antikörpern
JP4343473B2 (ja) * 1999-06-21 2009-10-14 日本メジフィジックス株式会社 血漿蛋白質に結合親和性を有する薬剤の投与方法並びに当該投与方法に用いられる製剤

Also Published As

Publication number Publication date
ES2290042T3 (es) 2008-02-16
EP1197227B1 (de) 2007-09-12
ATE372785T1 (de) 2007-09-15
DE60036382T4 (de) 2008-09-25
CA2376159C (en) 2010-09-14
WO2000078352A1 (fr) 2000-12-28
DE60036382T2 (de) 2008-06-12
JP4343473B2 (ja) 2009-10-14
US20060140857A1 (en) 2006-06-29
US7029653B1 (en) 2006-04-18
CA2376159A1 (en) 2000-12-28
EP1197227A1 (de) 2002-04-17
EP1197227A4 (de) 2002-12-04
EP1197227B9 (de) 2008-06-11

Similar Documents

Publication Publication Date Title
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
ATE361073T1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
ATE259226T1 (de) Zusammmensetzungen und verfahren zur verminderung der atmungsdepressionen und begleitender nebenmwirkungen von mu-opioid-verbindungen
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
ATE108680T1 (de) Therapeutisches system zur verzögerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii).
TR200000149T2 (tr) Serebral nörovasküler bozuklukların, müsküler baş ağrılarının önlenmesine yönelik kompozisyonlar
DE60036382D1 (de) Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
MX9706689A (es) Tratamiento de trastornos causados por el factor de crecimiento de citocina.
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
ATE228843T1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
SE9000207L (sv) Laekemedel samt anvaendningen av detsamma
GB9917290D0 (en) Pharmaceutical composition
DE59611212D1 (de) Transdermales therapeutisches system zur verabreichung von (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen salze
IL96161A0 (en) Application of n-methyl-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxide to the preparation of medicinal products intended for the treatment of coronary insufficiency
DE69808287T2 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
DE69729120D1 (de) Arzneipräparat und verfahren zur behandlung und vorbeugung von fybromyalgie und des chronischen ermüdungssyndrom
Cadman Set back for nerve growth factor

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NIHON MEDI-PHYSICS CO., LTD., TOKYO, JP

8364 No opposition during term of opposition